« Back
Investigating orthogonal in vitro analytical approaches to demonstrate bioequivalence (BE) of nasal suspension formulations
Investigating orthogonal in vitro analytical approaches to demonstrate bioequivalence (BE) of nasal suspension formulations
Submitted on 28 Aug 2018

Gonçalo Farias, Robert Price, William Ganley, Debbie Huck-Jones, Paul Kippax & Jagdeep Shur
University of Bath, Malvern Instruments Limited
This poster was presented at Drug Delivery to the Lungs conference
Poster Views: 156
View poster »
Poster Abstract
Nasal suspension drug products consist of API particles suspended in an aqueous system in the presence of a range of different excipients.

For suspension nasal products, the API particle size is a key critical material attribute, which will affect emitted API particle size and regional deposition of API in the nose. In addition, the particle size of the API will affect the rate of dissolution and permeability at site of deposition in the nasal epithelium and thereby systemic exposure of the API from the nose.

The paucity of validated methods for characterizing API specific drug particle size distribution (PSD) in nasal formulations has resulted in limited understanding of the relationship between API PSD, regional deposition in the nasal cavity, dissolution, and absorption of the API from the nose.

Although PSD can be readily determined by a number of methods prior to formulation into a finished product, the primary challenge has been to determine the PSD of the drug substance in the finished nasal aqueous suspension products in the presence of undissolved excipients[3]. Excipients often exhibit a broad PSD and a substantial number of excipient particles may exist in the same size range as the drug substance, thus complicating drug substance particle size determination. Morphology-directed Raman Spectroscopy (MDRS) is a promising approach for characterizing particle size of API in aqueous nasal spray suspension formulations. Morphological filters are used to allow the detection of a statistically relevant number of API particles. This approach allows the chemical identification of API in situ within complex nasal formulations which can directly benefit the BE requirements for ANDAs.

1. Li BV et al. AAPS J 2013, 15:875–883.
2. Doub WH, et al. Pharm. Res. 2012, 29:3122–3130.
3. Doub WH, et al. Pharm. Res. 2007, 24:934–945.
4. Rygg A, et al. Pharm. Res. 2015:1–13.
5. Mitchell J, et al. AAPS PharmSciTech 2011, 12:965–988.
6. Sharpe SA, et al. Drug Dev Ind Pharm 2003, 29:1005–1012.
7. Shur J,
Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Strategies for High-Titer Protein Expression Using the ExpiCHO and Expi293 Transient Expression Systems
Chao Yan Liu, Jian Liu, Wanhua Yan, Kyle Williston, Katy Irvin, Henry Chou, Jonathan Zmuda

A Chemically-Defined Baculovirus-Based Expression System for Enhanced Protein Production in Sf9 Cells
Maya Yovcheva, Sara Barnes, Kenneth Thompson, Melissa Cross, Katy Irvin, Mintu Desai, Natasha Lucki, Henry Chiou, Jonathan Zmuda

A New Method for the Reliable Detection of 13C Multiplets of Fluorine Containing Compounds
Dimitris Argyropoulos, Rostislav Pol, Vladimir Mikhailenko, and Sergey Golotvin

Nikita Gandotra

Things just keep changing: Family caregivers' perceptions of the impact of Huntington's disease on caregiver burden
Jess Kaplonyi, Dr Christopher Lind, Catherine Christian, Irene Scott